Labopharm monetizes Ryzolt royalty stream

Montreal-based Labopharm (TSX:DDS; NASDAQ:DDSS) has monetized the expected future royalty payment stream for its once-daily tramadol pain drug Ryzolt. Under the accord with U.S. partner Purdue Pharma, Labopharm will receive $5.3 million (U.S.) from Purdue in exchange for discontinuing future royalty payments on U.S. sales of Ryzolt. In addition, Labopharm will be released from future [...]

Labopharm partner loses tramadol patent appeal

The U.S. Court of Appeals for the Federal Circuit has ruled that Purdue Pharma Products’ patent claims for controlled-release tramadol, a pain medication, are invalid.  Purdue distributes Labopharm’s (TSX:DDS; NASDAQ:DDSS) tramadol drug Ryzolt in the U.S. Generic drug maker Par Pharmaceutical (NYSE:PRX) had argued that the patent claims should be deemed invalid because they were [...]